Clinical Trial Update: Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 adaptive-design trial evaluating safety and efficacy of treatment regimens with SM-020 for seborrheic keratosis is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seborrheic Keratosis

Drugs mentioned

• SM-020

Snippet

Sponsor: DermBiont, Inc. | Conditions: Seborrheic Keratosis | Phase 2 | Status: UNKNOWN